Idexx Laboratories (IDXX) EBITDA Margin (2009 - 2026)

Idexx Laboratories' EBITDA Margin history runs 18 years deep, the most recent figure standing at 31.78% for Q1 2026.

• In Q1 2026, EBITDA Margin rose 8.0% year-over-year to 31.78%; the TTM figure through Mar 2026 stood at 31.63% (up 248.0% YoY), while the FY2025 annual figure was 31.6%, up 265.0% from the prior year.
• EBITDA Margin for Q1 2026 stood at 31.78%, up from 28.94% in the prior quarter.
• The five-year high for EBITDA Margin was 33.62% in Q2 2025, with the low at 20.81% in Q2 2022.
• The 5-year median for EBITDA Margin is 30.07% (2023), against an average of 29.46%.
• The sharpest annual moves came in 2022 and 2023: EBITDA Margin slumped 1057 bps in 2022, then soared 1058 bps in 2023.
• Idexx Laboratories' EBITDA Margin stood at 27.34% in 2022, then declined by 0 bps to 27.21% in 2023, then climbed by 1 bps to 27.42% in 2024, then rose by 6 bps to 28.94% in 2025, then rose by 10 bps to 31.78% in 2026.
• Business Quant data shows IDXX's EBITDA Margin at 31.78% in Q1 2026, 28.94% in Q4 2025, and 32.11% in Q3 2025.